Abstract
The efficacy of ten daily injections of 500 or 500,000 U of recombinant interleukin 2 (IL-2) day-1 given 1.5 cm from the insertion of the sternocleidomastoid muscle on the mastoid was evaluated in 31 patients with recurrent head and neck squamous cell carcinoma. No toxic effects were noted. One complete response (CR) and three partial responses (PRs) were observed in the 16 patients who received 500 U of IL-2, whereas the higher dose was not effective. The CR was recorded in one of the seven patients with a oropharyngeal recurrence. Partial responses were obtained in 1/5 patients with hypopharyngeal recurrences, in 1/5 patients with oral cavity recurrences and 1/7 patients with laryngeal recurrences. The duration of the responses was 3-5 months and additional courses of ten injections of IL-2 had no further effect.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cortesina, G., De Stefani, A., Galeazzi, E. et al. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer 69, 572–576 (1994). https://doi.org/10.1038/bjc.1994.104
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.104
This article is cited by
-
Immuntherapie von Kopf-Hals-Karzinomen
HNO (2013)
-
A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma
Cancer Immunology, Immunotherapy (2012)
-
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen
Cancer Immunology, Immunotherapy (2012)
-
Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice
Breast Cancer Research (2007)
-
Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
British Journal of Cancer (2005)